Related Experiment Video
Updated: Jun 19, 2026
08:43
Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
Alzheimer's disease and neuronal network activity
Marc Gleichmann1, Mark P Mattson
1Laboratory of Neurosciences, National Institute on Aging, BRC, Suite 100, 251 Bayview Blvd, Baltimore, MD 21224, USA. gleichmannma@grc.nia.nih.gov
Neuromolecular Medicine
|November 4, 2009
Summary
Alzheimer's Disease research highlights how amyloid beta impacts neuronal networks, potentially causing seizures. Understanding these changes is key to developing new treatments for this neurodegenerative disease.
Area of Science:
- Neuroscience
- Molecular Biology
- Pathology
Background:
- The amyloid beta-peptide theory is central to Alzheimer's Disease (AD) research.
- Altered neuronal network activity is increasingly recognized as a key feature of AD.
- Increased epileptic seizures in AD patients and models suggest network dysfunction.
Purpose of the Study:
- To explore the role of amyloid beta in altering neuronal network activity in Alzheimer's Disease.
- To review the effects of amyloid beta on synaptic transmission and long-term potentiation.
- To discuss clinical aspects including functional MRI changes and seizure frequency in AD.
Main Methods:
- Review of basic research on amyloid beta's effects on synaptic transmission.
- Analysis of studies on neuronal network alterations in Alzheimer's Disease.
- Examination of clinical data on functional MRI and seizures in AD patients.
Main Results:
- Amyloid beta may directly impair glutamatergic synaptic transmission.
- Impaired long-term potentiation induction is linked to amyloid beta.
- Altered network activity, including seizures, is a significant symptom of AD.
Conclusions:
- Amyloid beta's disruption of synaptic function is a critical factor in Alzheimer's Disease pathogenesis.
- Understanding network hyperexcitability is crucial for AD therapeutic strategies.
- Further research into amyloid beta's effects on neuronal networks will advance AD treatment.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...